TN2012000549A1 - Substituted 5-fluoro-1h-pyrazolopyridines and use thereof - Google Patents

Substituted 5-fluoro-1h-pyrazolopyridines and use thereof

Info

Publication number
TN2012000549A1
TN2012000549A1 TNP2012000549A TN2012000549A TN2012000549A1 TN 2012000549 A1 TN2012000549 A1 TN 2012000549A1 TN P2012000549 A TNP2012000549 A TN P2012000549A TN 2012000549 A TN2012000549 A TN 2012000549A TN 2012000549 A1 TN2012000549 A1 TN 2012000549A1
Authority
TN
Tunisia
Prior art keywords
pyrazolopyridines
fluoro
substituted
prophylaxis
treatment
Prior art date
Application number
TNP2012000549A
Other languages
English (en)
Inventor
Markus Follmann
Johannes-Peter Stasch
Gorden Redlich
Jens Ackerstaff
Nils Griebenow
Walter Kroh
Andreas Knorr
Eva-Maria Becker
Frank Wunder
Volkhart Min-Jian Li
Elke Hartmann
Joachim Mittendorf
Karl-Heinz Schlemmer
Rolf Jautelat
Donald Bierer
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44119218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000549(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of TN2012000549A1 publication Critical patent/TN2012000549A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2012000549A 2010-05-26 2012-11-23 Substituted 5-fluoro-1h-pyrazolopyridines and use thereof TN2012000549A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010021637A DE102010021637A1 (de) 2010-05-26 2010-05-26 Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PCT/EP2011/058431 WO2011147809A1 (de) 2010-05-26 2011-05-24 Substituierte 5-fluor-1h-pyrazolopyridine und ihre verwendung

Publications (1)

Publication Number Publication Date
TN2012000549A1 true TN2012000549A1 (en) 2014-04-01

Family

ID=44119218

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000549A TN2012000549A1 (en) 2010-05-26 2012-11-23 Substituted 5-fluoro-1h-pyrazolopyridines and use thereof

Country Status (46)

Country Link
US (8) US8420656B2 (enExample)
EP (1) EP2576547B1 (enExample)
JP (1) JP5896991B2 (enExample)
KR (1) KR101862420B1 (enExample)
CN (1) CN102939289B (enExample)
AR (1) AR081628A1 (enExample)
AU (1) AU2011257335B2 (enExample)
BR (2) BR112012030010A2 (enExample)
CA (1) CA2800697C (enExample)
CL (1) CL2012003226A1 (enExample)
CO (1) CO6640226A2 (enExample)
CR (1) CR20120596A (enExample)
CU (1) CU24086B1 (enExample)
CY (2) CY1117372T1 (enExample)
DE (1) DE102010021637A1 (enExample)
DK (1) DK2576547T3 (enExample)
DO (1) DOP2012000299A (enExample)
EA (1) EA023631B9 (enExample)
EC (1) ECSP12012310A (enExample)
ES (1) ES2567795T3 (enExample)
FR (1) FR21C1038I2 (enExample)
GT (1) GT201200313A (enExample)
HR (1) HRP20160370T1 (enExample)
HU (2) HUE026912T2 (enExample)
IL (2) IL223050A (enExample)
JO (1) JO3199B1 (enExample)
LT (1) LTC2576547I2 (enExample)
LU (1) LUC00221I2 (enExample)
MA (1) MA34248B1 (enExample)
ME (1) ME02393B (enExample)
MX (1) MX2012013324A (enExample)
MY (1) MY164356A (enExample)
NL (1) NL301146I2 (enExample)
NO (1) NO2021032I1 (enExample)
NZ (1) NZ603800A (enExample)
PE (1) PE20130402A1 (enExample)
PH (1) PH12012502320A1 (enExample)
PL (1) PL2576547T3 (enExample)
RS (1) RS54704B1 (enExample)
SG (1) SG185460A1 (enExample)
SI (1) SI2576547T1 (enExample)
TN (1) TN2012000549A1 (enExample)
TW (1) TWI516263B (enExample)
UA (1) UA109660C2 (enExample)
UY (1) UY33396A (enExample)
WO (1) WO2011147809A1 (enExample)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
ES2693746T3 (es) 2009-11-27 2018-12-13 Adverio Pharma Gmbh Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo para su uso como principio activo farmacéutico
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
SG186749A1 (en) 2010-07-09 2013-02-28 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
EP3421470B8 (de) * 2011-11-25 2021-08-11 Adverio Pharma GmbH Substituierte 5-fluor-1h-pyrazolopyridine in kristalliner form
CN102491974B (zh) 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200352A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
JP6140738B2 (ja) 2012-03-06 2017-05-31 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アザ二環およびその使用
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
NZ702977A (en) 2012-07-20 2017-10-27 Bayer Pharma AG 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
WO2014012935A1 (de) 2012-07-20 2014-01-23 Bayer Pharma Aktiengesellschaft Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung
MX2015006856A (es) 2012-11-30 2016-02-17 Astellas Pharma Inc Compuestos imidazopiridina.
EP3760629A1 (en) 2013-02-21 2021-01-06 Adverio Pharma GmbH Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
MX2015010966A (es) 2013-03-01 2016-04-04 Bayer Pharma AG Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
EP3010907A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
TN2016000006A1 (en) 2013-07-10 2017-07-05 Bayer Pharma AG Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
EP3024455A1 (en) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
TW201605812A (zh) 2013-09-16 2016-02-16 拜耳製藥股份有限公司 經雙取代之三氟甲基嘧啶酮類及其用途
WO2015052065A1 (de) 2013-10-07 2015-04-16 Bayer Pharma Aktiengesellschaft Cyclische thienouracil-carboxamide und ihre verwendung
WO2015088885A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2015088886A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
WO2015150350A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
EP3126340A2 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
WO2015187470A1 (en) 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
JP6618530B2 (ja) 2014-09-09 2019-12-11 バイエル ファーマ アクチエンゲゼルシャフト 置換ｎ，２−ジアリールキノリン−４−カルボキサミドおよび抗炎症剤としてのその使用
WO2016046157A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
CN107074783B (zh) 2014-11-03 2020-06-05 拜耳制药股份公司 羟烷基取代的苯基三唑衍生物及其用途
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
WO2016113205A1 (de) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituierte pentafluorethylpyrimidinone und ihre verwendung
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
BR112017023855A2 (pt) 2015-05-06 2018-07-17 Bayer Pharma Aktiengesellschaft o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc)
WO2016191334A1 (en) 2015-05-27 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
LT3325013T (lt) 2015-07-23 2020-11-10 Bayer Pharma Aktiengesellschaft Tirpios guanilatciklazės (sgc) stimuliatoriai/aktyvatoriai derinyje su nep inhibitoriumi ir (arba) angiotenzino aii antagonistu ir jų naudojimas
US10759794B2 (en) 2015-12-10 2020-09-01 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
JP2018538296A (ja) 2015-12-10 2018-12-27 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用
CN108463224A (zh) 2015-12-14 2018-08-28 铁木医药有限公司 sGC刺激剂用于胃肠功能障碍治疗的应用
CN105461715B (zh) * 2015-12-15 2017-03-29 郑州大明药物科技有限公司 一种利奥西呱中间体的合成方法
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017121692A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte sulfamide und ihre verwendung
IL260701B (en) * 2016-02-01 2022-09-01 Ironwood Pharmaceuticals Inc Use of certain sgc stimulators and salts thereof in the preparation of medicaments for the treatment of nonalcoholic steatohepatitis (nash)
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
AR108263A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2017191115A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
JOP20170113B1 (ar) 2016-05-09 2023-03-28 Bayer Pharma AG مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
EP3458063A4 (en) 2016-05-18 2020-02-26 Merck Sharp & Dohme Corp. METHOD FOR USE OF TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISEASES
EP3481823B1 (de) 2016-07-11 2020-10-28 Bayer Pharma Aktiengesellschaft 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
EP3296298A1 (de) 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
SG11201902588PA (en) 2016-09-23 2019-05-30 Bayer Ag N3-Cyclically Substituted Thienouracils And Use Thereof
CA3039734A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc stimulators and mineralocorticoid receptor antagonists
JP7237823B2 (ja) 2016-10-11 2023-03-13 バイエル ファーマ アクチエンゲゼルシャフト Ｓｇｃアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
WO2018073144A1 (en) 2016-10-20 2018-04-26 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EP3338803A1 (de) 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
EP3338764A1 (de) 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
WO2018153899A1 (de) * 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
PH12019502314A1 (en) 2017-04-10 2020-10-26 Bayer Ag Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
CA3056501A1 (en) 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
CN108690016B (zh) * 2017-04-11 2022-08-12 广东东阳光药业有限公司 吡唑并吡啶类化合物及其用途
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
EP3700899A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
US11331314B2 (en) 2017-10-24 2022-05-17 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
US11173151B2 (en) 2017-10-24 2021-11-16 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700903A1 (de) * 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituierte imidazopyridinamide und ihre verwendung
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
SI3700913T1 (sl) 2017-10-24 2022-02-28 Bayer Aktiengesellschaft Predzdravila derivatov substituiranega triazola in njihove uporabe
US11149023B2 (en) 2017-10-24 2021-10-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3084411A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3707141B1 (de) 2017-11-07 2021-12-22 Bayer Aktiengesellschaft Substituierte 2,4-dihydro-3h-1,2,4-triazol-3-one und ihre verwendung
PE20211391A1 (es) 2017-12-01 2021-07-27 Bayer Pharma AG Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico
KR102745228B1 (ko) * 2017-12-19 2024-12-19 사이클리온 테라퓨틱스, 인크. sGC 자극제
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
CA3098475A1 (en) * 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EP3566704A1 (en) 2018-05-11 2019-11-13 Bayer Aktiengesellschaft The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases
CA3100096A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
CN112469412A (zh) 2018-05-17 2021-03-09 拜耳公司 取代的二氢吡唑并吡嗪甲酰胺衍生物
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
BR112021000358A2 (pt) 2018-07-11 2021-04-06 Cyclerion Therapeutics, Inc. Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais
EP3826627B1 (de) 2018-07-24 2023-10-18 Bayer Aktiengesellschaft Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
EP3826619A1 (de) 2018-07-24 2021-06-02 Bayer Aktiengesellschaft Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
EA202191480A1 (ru) 2018-11-27 2021-08-27 Байер Акциенгезельшафт Способ получения фармацевтических лекарственных форм, содержащих ингибиторы task-1- и task-3-каналов, и их применение для терапии нарушений дыхания
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
JP7667091B2 (ja) 2019-05-07 2025-04-22 バイエル・アクチエンゲゼルシヤフト Ｍａｓｐ阻害化合物およびその使用
WO2020245342A1 (en) 2019-06-07 2020-12-10 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
TWI867088B (zh) 2019-11-06 2024-12-21 德商拜耳廠股份有限公司 經取代之雜環甲醯胺及其用途
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
US20230067593A1 (en) * 2020-02-03 2023-03-02 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3 -yl]pyrimidin-5-yl} carbamate
WO2021167458A1 (en) 2020-02-21 2021-08-26 Universiteit Maastricht Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme
WO2021172982A1 (en) 2020-02-26 2021-09-02 Universiteit Maastricht Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
WO2021195403A1 (en) 2020-03-26 2021-09-30 Cyclerion Therapeutics, Inc. Deuterated sgc stimulators
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
US20240010684A1 (en) 2020-11-04 2024-01-11 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
US20240109864A1 (en) 2020-12-10 2024-04-04 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
MX2023006902A (es) 2020-12-10 2023-06-26 Bayer Ag Uso de activadores de sgc para el tratamiento de enfermedades oftalmologicas.
CR20230242A (es) 2020-12-10 2023-07-19 Bayer Ag Ácidos pirazol piperidin carboxílicos sustituidos
EP4011874A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
JP2024516623A (ja) 2021-04-20 2024-04-16 ティセント セラピューティクス インコーポレーテッド ｓＧＣ刺激剤でのＣＮＳ疾患の処置
CR20230532A (es) 2021-04-20 2024-03-22 Tisento Therapeutics Inc ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC)
US20240352014A1 (en) 2021-08-31 2024-10-24 Teva Pharmaceuticals International Gmbh Solid state forms of vericiguat and process for preparation thereof
KR20240144177A (ko) 2021-12-29 2024-10-02 바이엘 악티엔게젤샤프트 (5s)-{[2-(4-카르복시페닐)에틸][2-(2-{[3-클로로-4'-(트리플루오로메틸)비페닐-4-일]메톡시}페닐)에틸]아미노}-5,6,7,8-테트라히드로퀴놀린-2-카르복실산및 약학적 활성 화합물로서 사용하기 위한 이의 결정질 형태를 제조하는 방법
IL313924A (en) 2021-12-29 2024-08-01 Bayer Ag Pharmaceutical dry powder inhalation formulation
EP4456896A1 (en) 2021-12-29 2024-11-06 Bayer Aktiengesellschaft Treatment of cardiopulmonary disorders
ES2956054B2 (es) * 2022-05-03 2024-07-01 Moehs Iberica Sl 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT
TW202412753A (zh) 2022-06-09 2024-04-01 德商拜耳廠股份有限公司 用於治療女性心臟衰竭合併保留射出分率的可溶性鳥苷酸環化酶活化劑
WO2024086179A1 (en) 2022-10-18 2024-04-25 Tisento Therapeutics, Inc. Pyrimidine sgc stimulators
CN120112293A (zh) 2022-10-18 2025-06-06 帝善多制药公司 使用sGC刺激剂治疗线粒体疾病
CN116239609A (zh) * 2022-12-06 2023-06-09 山东百诺医药股份有限公司 一种维立西呱的关键杂质及其制备方法
TW202529751A (zh) 2023-09-28 2025-08-01 德商拜耳廠股份有限公司 經取代之雜環醯胺及其用途
WO2025114276A1 (en) 2023-12-01 2025-06-05 Krka, D.D., Novo Mesto Solid oral composition comprising vericiguat
WO2025132065A1 (en) 2023-12-20 2025-06-26 Adverio Pharma Gmbh Dose regimen for vericiguat
CN117924280B (zh) * 2024-03-20 2024-07-12 中国人民解放军军事科学院军事医学研究院 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01198481A (ja) * 1988-02-01 1989-08-10 Canon Inc マイクロ波プラズマｃｖｄ法による堆積膜形成法
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
EP0463754A1 (en) 1990-06-25 1992-01-02 Rohm And Haas Company Stabilization of glutarimide polymers
DK181190D0 (da) 1990-07-30 1990-07-30 Lundbeck & Co As H 3-aryl-indol- eller 3-aryl-indazolderivater
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
CA2268394C (en) 1996-10-14 2008-03-25 Bayer Aktiengesellschaft New heterocyclylmethyl-substituted pyrazol derivates
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1999024433A1 (de) 1997-11-12 1999-05-20 Bayer Aktiengesellschaft 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
WO2002042299A1 (de) 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Neue lactam-substituierte pyrazolopyridinderivate
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
EP1448557A4 (en) 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003076408A2 (en) 2002-03-08 2003-09-18 Abbott Laboratories Indazole derivatives that are activators of soluble guanylate cyclase
GR1004350B (el) * 2002-03-29 2003-09-26 Συσκευη εισπνοων ξηρης σκονης
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
DE10242941A1 (de) 2002-09-16 2004-03-18 Bayer Ag Substituiertes Pyrazolderivat
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
EP3406596A1 (en) 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
CA2521695C (en) 2003-05-09 2011-08-16 Asahi Glass Company, Limited Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CN100355732C (zh) 2003-11-03 2007-12-19 上海药明康德新药开发有限公司 2－氯－5－氟－烟酸酯及酸的制备方法
DE10351903A1 (de) 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
GB0403819D0 (en) 2004-02-20 2004-03-24 Merck Sharp & Dohme New compounds
US7514463B2 (en) 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP1799210A1 (en) 2004-10-05 2007-06-27 Bayer HealthCare AG A guanylate cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasconstriction
DE102005047945A1 (de) 2005-07-16 2007-01-18 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen
KR20080030669A (ko) 2005-07-18 2008-04-04 바이엘 헬스케어 아게 신장병의 예방 또는 치료를 위한 가용성 구아닐레이트시클라제 활성화제 및 자극제의 신규 용도
DE102006021733A1 (de) 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
WO2009000832A2 (en) 2007-06-25 2008-12-31 Boehringer Ingelheim International Gmbh Chemical compounds
CA2694499A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP2011513483A (ja) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
AR077898A1 (es) 2009-08-26 2011-09-28 Nycomed Gmbh Metilpirrolopirimidincarboxamidas
UY33040A (es) 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
ES2693746T3 (es) 2009-11-27 2018-12-13 Adverio Pharma Gmbh Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo para su uso como principio activo farmacéutico
AU2010330813B2 (en) 2009-12-18 2016-04-28 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2576548B1 (en) * 2010-05-26 2015-06-24 Adverio Pharma GmbH THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc)
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
SG186749A1 (en) 2010-07-09 2013-02-28 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040234A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
EP2714660B1 (en) 2011-05-31 2018-09-26 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
US8859569B2 (en) 2011-09-02 2014-10-14 Bayer Pharma Aktiengesellschaft Substituted annellated pyrimidines and use thereof
EP3421470B8 (de) 2011-11-25 2021-08-11 Adverio Pharma GmbH Substituierte 5-fluor-1h-pyrazolopyridine in kristalliner form
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung

Also Published As

Publication number Publication date
UA109660C2 (xx) 2015-09-25
CU24086B1 (es) 2015-03-30
HK1182112A1 (zh) 2013-11-22
UY33396A (es) 2011-12-30
PL2576547T3 (pl) 2016-07-29
IL223050A0 (en) 2013-02-03
US20130237551A1 (en) 2013-09-12
MA34248B1 (fr) 2013-05-02
LUC00221I2 (enExample) 2024-10-04
LTPA2021518I1 (enExample) 2021-09-10
JP5896991B2 (ja) 2016-03-30
DOP2012000299A (es) 2013-03-31
TW201210592A (en) 2012-03-16
US9266885B2 (en) 2016-02-23
LTC2576547I2 (enExample) 2022-10-25
NZ603800A (en) 2014-10-31
EP2576547B1 (de) 2016-01-27
ME02393B (me) 2016-09-20
NL301146I1 (nl) 2021-12-08
MY164356A (en) 2017-12-15
IL249669B (en) 2020-05-31
PE20130402A1 (es) 2013-04-13
KR101862420B1 (ko) 2018-07-04
EA023631B1 (ru) 2016-06-30
US20160129004A1 (en) 2016-05-12
US20120022084A1 (en) 2012-01-26
US11439642B2 (en) 2022-09-13
US9993476B2 (en) 2018-06-12
BR122020023470B1 (pt) 2022-07-12
DE102010021637A1 (de) 2011-12-01
US20200397785A1 (en) 2020-12-24
CA2800697C (en) 2018-08-07
CO6640226A2 (es) 2013-03-22
ES2567795T3 (es) 2016-04-26
CY2021021I2 (el) 2021-12-31
SI2576547T1 (sl) 2016-05-31
ECSP12012310A (es) 2012-12-28
FR21C1038I2 (fr) 2022-09-02
AU2011257335A1 (en) 2012-12-20
US20150080414A1 (en) 2015-03-19
TWI516263B (zh) 2016-01-11
CN102939289A (zh) 2013-02-20
IL249669A0 (en) 2017-02-28
CA2800697A1 (en) 2011-12-01
JO3199B1 (ar) 2018-03-08
CL2012003226A1 (es) 2013-07-26
NO2021032I1 (no) 2021-09-06
FR21C1038I1 (enExample) 2021-10-15
CY1117372T1 (el) 2017-04-26
CU20120161A7 (es) 2013-02-26
US20220409618A1 (en) 2022-12-29
EA201291336A1 (ru) 2013-04-30
MX2012013324A (es) 2012-12-05
US20180263981A1 (en) 2018-09-20
US12064429B2 (en) 2024-08-20
EP2576547A1 (de) 2013-04-10
NL301146I2 (nl) 2022-07-06
US8420656B2 (en) 2013-04-16
HRP20160370T1 (hr) 2016-05-06
HUS2100032I1 (hu) 2021-09-28
DK2576547T3 (en) 2016-04-25
JP2013530150A (ja) 2013-07-25
AU2011257335B2 (en) 2015-12-03
HUE026912T2 (en) 2016-07-28
WO2011147809A1 (de) 2011-12-01
CN102939289B (zh) 2016-01-20
SG185460A1 (en) 2012-12-28
PH12012502320A1 (en) 2013-02-11
CY2021021I1 (el) 2021-12-31
RS54704B1 (sr) 2016-08-31
KR20130116000A (ko) 2013-10-22
EA023631B9 (ru) 2017-04-28
US8921377B2 (en) 2014-12-30
CR20120596A (es) 2013-04-22
BR112012030010A2 (pt) 2020-09-01
IL223050A (en) 2017-01-31
US20170273977A1 (en) 2017-09-28
US10736896B2 (en) 2020-08-11
AR081628A1 (es) 2012-10-10
GT201200313A (es) 2014-01-31

Similar Documents

Publication Publication Date Title
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
PH12013501143A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
PH12013500055A1 (en) Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
PH12015501703A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
WO2013104598A3 (de) Substituierte, annellierte imidazole und pyrazole und ihre verwendung
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
UA115887C2 (uk) АМІНОЗАМІЩЕНІ ІМІДАЗО[1,2-а]ПІРИДИНКАРБОКСАМІДИ І ЇХ ЗАСТОСУВАННЯ
PH12015500106A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
PH12014500460A1 (en) Substituted annellated pyrimidine and the use thereof
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
PH12017502224A1 (en) Positive allosteric modulators of muscarinic md receptor
TN2011000595A1 (en) Substituted piperidines
PH12016500608A1 (en) Cyclic thienouracil-carboxamides and use thereof
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
TN2011000596A1 (en) Substituted piperidines
MY196473A (en) 7-Substituted 1-Aryl-Naphthyridine-3-Carboxylic Acid Amides and use Thereof
MX2013002485A (es) Fenilacetamidas y fenilpropanamidas sustituidas y su uso.
TN2015000523A1 (en) Substituted benzoxazoles
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof